In a report released today, Marie Thibault from BTIG maintained a Buy rating on Abbott Labs (ABT), with a price target of $140.00. The company’s shares closed last Friday at $116.65.
According to TipRanks.com, Thibault is a 5-star analyst with an average return of 66.6% and a 55.9% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Edwards Lifesciences.
Abbott Labs has an analyst consensus of Strong Buy, with a price target consensus of $137.88.
See today’s analyst top recommended stocks >>
Abbott Labs’ market cap is currently $207.3B and has a P/E ratio of 36.60. The company has a Price to Book ratio of -51.78.
Based on the recent corporate insider activity of 229 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Abbott Laboratories offers a diversified line of healthcare products. It operates through four reportable segments: Established Pharmaceutical Products International (includes international sales of branded generic pharmaceutical products), Nutritional Products Diagnostic Products and Medical Devices. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
Read More on ABT:
